Senator Charles Grasslet and the US senate committe on finance has called for tougher regulation on ghostwriting in medical journals. The report says that as journals influence prescribing, undisclosed funding by companies can lead to journals inadvertantly promoting sales of a company’s product. He goes on to state, that once strong policy is in place, the difficulty will be with compliance.

BMJ 2010, 340, c3504